Dee the result of last similar formation highlighted in the chart.
Operación activa:
Glenmark Pharma reported better than expected EBITDA and EBITDA margin.
· Q1 net profit Rs254cr (up 132% YoY) – expectation Rs144cr,
· Ebitda Rs478cr (up 40% YoY) – expectation Rs372cr,
· EBITDA margin 20.4% vs 14.5% (YoY) – expectation 14.8%
· Income Rs Rs2345cr (up 1% YoY)- expectation Rs2515cr
· Q1 net profit Rs254cr (up 132% YoY) – expectation Rs144cr,
· Ebitda Rs478cr (up 40% YoY) – expectation Rs372cr,
· EBITDA margin 20.4% vs 14.5% (YoY) – expectation 14.8%
· Income Rs Rs2345cr (up 1% YoY)- expectation Rs2515cr